Hepatitis B and hepatitis C co-infection in patients with HIV

Reviews in Medical Virology

Volumn 11, Issue 4, 2001, Pages 253-270

  Martnez, E Herrero ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DISEASE COURSE; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER DISEASE; MORTALITY; PATHOGENESIS; PREVALENCE; REVIEW; SUPERINFECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE SUSCEPTIBILITY; DISEASE TRANSMISSION, HORIZONTAL; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER DISEASES;

EID: 0034897385     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.323     Document Type: Review

References (173)

1. Molecular biology of hepatitis B virus
2. Natural and iatrogenic variation in hepatitis B virus
3. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate
4. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
5. Global programme for control of hepatitis B infection
6. Hepatitis B: Evolving epidemiology and implications for control
7. Transmission of hepatitis B to chimpanzees by hepatitis B surface antigen-positive saliva and semen
8. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection
9. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis
10. Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B
11. The hepatitis B virus
12. Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants
13. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
14. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis
15. Intrahepatic T cells in hepatitis B: Viral control versus liver cell injury
16. Molecular virology and pathogenesis of hepatitis B
17. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen
18. To kill or to cure: Options in host defense against viral infection
19. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection
20. Hepatitis B virus. The major etiology of hepatocellular carcinoma
21. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis
22. Transactivation by hepatitis B virus may contribute to hepatocarcinogenesis
23. HBx gene of hepatitis B virus induces liver cancer in transgenic mice
24. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
25. The hepatitis B virus X gene induces p53-mediated programmed cell death
26. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene
27. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis
28. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
29. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
30. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors
31. Oral treatment for hepatitis B gets approval in the United States
32. A preliminary trial of lamivudine for chronic hepatitis B infection
33. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
34. Lamivudine as initial treatment for chronic hepatitis B in the United States
35. A placebo controlled study of lamivudine and interferon-alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy
36. A one-year trial of lamivudine for chronic hepatitis B
37. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
38. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
39. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B
40. Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients
41. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
42. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
43. Lamivudine treatment of chronic hepatitis B
44. An open label pilot study of the safety and efficacy of adefovir dipivoxil in HIV/HBV co-infected patients with lamivudine resistant HIV
45. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients
46. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha
47. A study of oral entecavir given for 28 days in both treatment-naive and pre-treated subjects with chronic hepatitis
48. Effectiveness of a low dose of entecavir in treating recurrent viremia in chronic hepatitis B
49. Sustained antiviral efficacy in the woodchuck model of chronic hepatitis infection following long-term entecavir (BMS-200475) treatment
50. Expression of regeneration and tolerance factor correlates directly with human immunodeficiency virus infection and inversely with hepatitis C virus infection
51. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value
52. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiency virus: No evidence of faster progression to AIDS
53. The prevalence of hepatitis B and C in HIV-positive Greek patients: Relationship to survival of deceased AIDS patients
54. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection
55. HBsAg as the antigen component of circulating immune complexes in HIV-infected patients
56. HIV and hepatitis virus infection
57. Novel compounds in preclinical/early clinical development for the treatment of HIV infections
58. HIV nucleoside analogues: New adverse effects on mitochondria?
59. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: Ultrastructural and biochemical findings
60. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection
61. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
62. Two decades of HIV infection in a cohort of haemophilic individuals: Clinical outcomes and response to highly active antiretroviral therapy
63. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection
64. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy
65. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
66. Virus taxonomy
67. Internal ribosome entry site within hepatitis C virus RNA
68. Replication of hepatitis C virus
69. A proposed system for the nomenclature of hepatitis C viral genotypes
70. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes
71. The epidemiology of antibody to hepatitis C in Egypt
72. Epidemiology of hepatitis C in the United States
73. The risk of transfusion-transmitted viral infections
74. The detection, transmission, and outcome of hepatitis C virus infection
75. Detection of hepatitis C virus in the semen of infected men
76. Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland
77. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia
78. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women
79. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV)
80. Hepatitis C virus infection in spouses of patients with type C chronic liver disease
81. Hepatitis C virus infection ih sexually promiscuous groups
82. Hepatitis C prevalence in HIV-infected patients: A cross-sectional analysis of the US adult clinical trials group
83. Analysis of successful immune responses in persons infected with hepatitis C virus
84. Hepatitis C virus-specific CD4(-) T cells: Do they help or damage?
85. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C
86. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
87. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus
88. Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells
89. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients
90. Detection of type 2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity
91. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
92. Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection
93. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
94. Immunopathogenesis of hepatitis C virus infection
95. Pathogenesis of hepatocellular damage in chronic hepatitis C virus infection
96. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection
97. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines
98. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C
99. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers
100. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
101. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals
102. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C
103. The role of the hepatitis C virus glycoproteins in infection
104. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis
105. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor
106. Apoptosis and viral hepatitis
107. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase
108. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice
109. Profiling gene expression pattern of a human hepatocyte cell line in response to hepatitis C virus core protein expression using cDNA microarrays
110. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV)
111. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade
112. Outcome of acute symptomatic non-A, non-B hepatitis: A 13-year follow-up study of hepatitis C virus markers
113. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis
114. The long-term pathological evolution of chronic hepatitis C
115. Natural course of chronic hepatitis C
116. Clinical outcomes after transfusion-associated hepatitis C
117. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
118. 45-Year follow-up of hepatitis C virus infection in healthy young adults
119. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
120. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
121. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
122. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
123. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
124. Racial differences in responses to therapy with interferon in chronic hepatitis C
125. The response to interferon + ribavirin re-treatment for chronic hepatitis C in interferon non-responders is not influenced by race
126. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
127. Sustained HCV eradication after interleukin-2 therapy in patients with HIV/HCV coinfection
128. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients
129. Efficacy of interferon plus ribavirin combination treatment and impact on HIV infection in hemophiliacs with chronic hepatitis C and under HAART
130. Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection
131. Treatment of hepatitis C with interferon and ribavirin
132. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report
133. Erythropoietin use for ribavirin/interferon induced anaemia in patients with hepatitis C
134. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
135. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
136. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy
137. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection
138. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy
139. Change in transaminases in hepatitis C
140. Can HCV affect the efficacy of anti-HIV treatment?
141. HCV and HIV co-infection: Prevalence, genotype distribution and severity of liver disease in an urban HIV clinic
142. Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy
143. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro
144. PEG interferonalpha 2B pharmacokinetics, safety and preliminary efficacy data [abstract 116]
145. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus
146. The progression of HCV-associated liver disease in a cohort of haemophilic patients
147. Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease
148. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters
149. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus
150. Red fingers syndrome in patients with HIV and hepatitis C infection
151. Prevalence of cryoglobulins and hepatitis C virus infection in HIV-infected patients
152. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985
153. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
154. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: Influence of antiretroviral therapy
155. Detection of hepatitis C virus RNA sequences in B-cell non-Hodgkin lymphoma
156. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells
157. The CD19/CR2/TAPA-1 complex of B lymphocytes: Linking natural to acquired immunity
158. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment
159. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users
160. Towards a solution for hepatitis C virus hypervariability: Mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants
161. HCV quasispecies as a mechanism of rapidly progressive liver disease in patients infected with the human immunodeficiency virus
162. Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies
163. Identification and quantitation of HIV-1 in the liver of patients with AIDS
164. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice
165. Does HIV tat protein also regulate genes of other viruses present in HIV infection?
166. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study
167. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs
168. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men
169. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1
170. The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment
171. CCR5delta32 mutation protective against HIV, but bad for hepatitis C virus?
172. Chronic hepatitis B virus infection: Treatment strategies for the next millennium
173. Viral escape and the failure of cellular immune responses